1. An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. (3rd July 2014) Authors: Moore, Kenneth T.; Vaidyanathan, Seema; Natarajan, Jaya; Ariyawansa, Jay; Haskell, Lloyd; Turner, Kenneth C. Journal: Journal of clinical pharmacology Issue: Volume 54:Number 12(2014:Dec.) Page Start: 1407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Issue 4 (16th May 2014) Authors: Moore, Kenneth T.; Krook, Mark A.; Vaidyanathan, Seema; Sarich, Troy C.; Damaraju, C. V.; Fields, Larry E. Journal: Clinical pharmacology in drug development Issue: Volume 3:Issue 4(2014:Jul./Aug.) Page Start: 321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. (June 2015) Authors: Moore, Kenneth Todd; Byra, William; Vaidyanathan, Seema; Natarajan, Jaya; Ariyawansa, Jay; Salih, Hiba; Turner, Kenneth C. Journal: British journal of clinical pharmacology Issue: Volume 79:Number 6(2015:Jun.) Page Start: 907 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗